A Phase I/II Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

NCT07123454 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

91

Enrollment

INDUSTRY

Sponsor class

Conditions

B-cell Non-Hodgkin Lymphoma

Interventions

DRUG: AZD4512

Sponsor

AstraZeneca